MA, C. Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier?. Canadian IBD Today, Toronto, Canada, v. 1, n. S05, p. 2–7, 2023. DOI: 10.58931/cibdt.2023.1S0510. Disponível em: https://canadianibdtoday.com/article/view/1-s05-ma. Acesso em: 5 may. 2024.